Search Results

Erbitux [cetuximab] is to be funded by the Ontario Government as a therapy for metastatic colorectal cancer

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 591, 2009-11-14 , pp. 14-14(1)

Publisher: Adis International

Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy

Authors: Mugabe, Clement; Hadaschik, Boris A.; Kainthan, Rajesh K.; Brooks, Donald E.; So, Alan I.; Gleave, Martin E.; Burt, Helen M.

Source: BJU International, Volume 103, Number 7, April 2009 , pp. 978-986(9)

Publisher: Blackwell Publishing

Cetuximab launched for mCRC, approved for SCCHN.

Source: Inpharma, Volume 1, Number 1663, 2008-11-08 , pp. 22-22(1)

Publisher: Adis International

Emerging therapies drive growth in melanoma market

Source: Inpharma, Volume 1, Number 1656, 2008-09-20 , pp. 7-7(1)

Publisher: Adis International

Cetuximab improves OS in head and neck cancer

Source: Inpharma, Volume 1, Number 1657, 2008-09-27 , pp. 17-17(1)

Publisher: Adis International

Cetuximab launched in Japan for advanced colorectal cancer

Source: Inpharma, Volume 1, Number 1657, 2008-09-27 , pp. 23-23(1)

Publisher: Adis International

Emerging therapies drive growth in melanoma market

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 563, 2008-10-04 , pp. 10-10(1)

Publisher: Adis International

Saxagliptin applications lodged in the US and EU.

Source: Inpharma, Volume 1, Number 1649, 2008-08-02 , pp. 22-22(1)

Publisher: Adis International

Prasugrel FDA approval decision: for whom is the timing out?

Source: Inpharma, Volume 1, Number 1644, 2008-06-28 , pp. 8-8(1)

Publisher: Adis International

Novel antiplatelet agents may be preferable post-MI, says report

Source: Inpharma, Volume 1, Number 1639, 2008-05-24 , pp. 2-2(1)

Publisher: Adis International

Bevacizumab plus paclitaxel/carboplatin is predicted to become the clinical gold-standard for advanced ovarian cancer in 2011

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 552, 2008-05-03 , pp. 10-10(1)

Publisher: Adis International

Bevacizumab plus paclitaxel/carboplatin is predicted to become the clinical gold-standard for advanced ovarian cancer in 2011

Source: Inpharma, Volume 1, Number 1637, 2008-05-10 , pp. 2-2(1)

Publisher: Adis International

The US FDA has approved aripiprazole

Source: Inpharma, Volume 1, Number 1628, 2008-03-08 , pp. 18-18(1)

Publisher: Adis International

The CHMP has issued a positive opinion for clopidogrel

Source: Inpharma, Volume 1, Number 1629, 2008-03-15 , pp. 18-18(1)

Publisher: Adis International

Dasatinib and nilotinib showed promising results in the first-line treatment of chronic myeloid leukaemia (CML), compared with standard therapy

Source: Inpharma, Volume 1, Number 1618, 2007-12-15 , pp. 6-6(1)

Publisher: Adis International

The addition of percutaneous coronary intervention (PCI) to medical therapy results in a significant reduction in ischaemia

Source: Inpharma, Volume 1, Number 1613, 2007-11-10 , pp. 4-4(1)

Publisher: Adis International

Cetuximab [Erbitux] will be the gold standard for the treatment of squamous cell carcinoma of the head and neck by 2010

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 533, 2007-07-28 , pp. 10-10(1)

Publisher: Adis International

The addition of cetuximab to first-line, platinum-based chemotherapy increases benefits for patients with head and neck cancer

Source: Inpharma, Volume 1, Number 1584, 2007-04-21 , pp. 20-20(1)

Publisher: Adis International

The GVAX cancer vaccine plus ipilimumab is active in the treatment of patients with advanced prostate cancer

Source: Inpharma, Volume 1, Number 1577, 2007-03-03 , pp. 8-8(1)

Publisher: Adis International

AIDS Healthcare Foundation, the US' largest AIDS group has launched an advertising campaign criticising Bristol-Myers Squibb for charging four times as much for lifesaving AIDS drugs in Mexico than in least developed countries.

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 523, 2007-03-10 , pp. 10-10(1)

Publisher: Adis International